Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 1997

View Archived Issues

SKB discloses improved antihyperlipidemic agent

Improved immunomodulating agent described by SKB

Antifungal agents from Nihon Nohyaku

Alcon prepares carbonic anhydrase inhibitors

Antiestrogenics from Schering AG

Boehringer Mannheim reports new antiplatelet agents

Somatostatin receptor antagonists prepared by Novartis

Small, specific inhibitors of VLA4-mediated cell adhesion from Biogen

Antiherpesvirus agent from Roche

Guilford reports 1996 year-end results

NeuroSearch profit announcement in 1996

Neurogen reports 1996 financial results

Genzyme Transgenics reports record fourth-quarter revenues

Genelabs Technologies reports 1996 fourth-quarter and year-end results

Long-acting injectable antifungal enters phase II trials

SS Pharm./Torii developing new antiallergic agent

Zeria and Lilly seek OTC switch for Asinon

Antiparkinson Rx from Sumitomo in pivotal European trials

Pharma Mar product update

Fluticasone associated with more adrenal suppression than budesonide

Cortecs signs oral delivery R&D agreement

Biosite Diagnostics licenses Scios technology

Matrix's radiation enhancer enters phase I/II

Clinical trial results for Neuprex in hepatectomy and meningococcemia

First live oral cholera vaccine approved in Canada

Pharmacopeia achieves milestone in collaboration with Schering-Plough

Banner Pharmacaps granted rights to softgel drug delivery system

Aastrom CPS enters clinical trials in Europe

Neugenesis granted patent for combinatorial biology platform

Visible Genetics and Consolidated Laboratory Services develop HIV tests

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...